drugset
drugset / Trial / NCT06672523

A Study to Evaluate the Mass Balance, Metabolism, Elimination, and Drug Levels of [14C]-BMS-986504 (MRTX1719) in Participants With Advanced Solid Tumors With Homozygous Methylthioadenosine Phosphorylase Deletion

NCT06672523 ↗

Phase 1 Recruiting 8 enrolled Bristol-Myers Squibb
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the mass balance, metabolism, elimination, and drug levels of \[14C\]-BMS-986504 (MRTX1719) in participants with advanced solid tumors with homozygous methylthioadenosine phosphorylase deletion.

Timeline

Start
2025-03-24
Primary completion
2027-10-25
Completion
2027-10-25

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-986504 Unknown — Oral

Indications

No indication recorded.